天境生物上涨11.01%，报3.741美元/股，总市值4.30亿美元

Group 1 - The stock price of Tianjing Biological (IMAB) increased by 11.01% on August 6, reaching $3.741 per share, with a trading volume of $4.6017 million and a total market capitalization of $430 million [1] - As of December 31, 2023, Tianjing Biological reported total revenue of 27.644 million RMB, representing a year-on-year growth of 112.48%, while the net profit attributable to the parent company was -1.466 billion RMB, showing a year-on-year increase of 41.54% [1] Group 2 - Tianjing Biological is scheduled to disclose its fiscal year 2024 interim report on August 28, with the actual disclosure date subject to the company's announcement [2] - The company is an offshore holding parent company that operates through its domestic subsidiary, focusing on innovative biopharmaceuticals in the fields of tumor immunity and autoimmune diseases [2] - Tianjing Biological aims to develop innovative biopharmaceuticals with "first-in-class" and "best-in-class" potential globally, striving to fill clinical treatment gaps and improve the quality of life for patients worldwide [2]